April 3, 2013New England Journal of Medicine705 citations
View Full PaperHepatotoxicity with Combination of Vemurafenib and Ipilimumab
Key Points
Key points are not available for this paper at this time.
Abstract
The independent mechanisms of action and largely nonoverlapping toxicity profiles of vemurafenib and ipilimumab made it logical to test them together in a study of patients with melanoma. An unexpected level of hepatic toxicity caused the early termination of the study.